Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
In a randomised placebo-controlled trial assess effects of zoledronic acid for prevention of
bone and muscle loss after bariatric surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Stinus Gadegaard Hansen
Collaborators:
Department of Endocrinology, Odense University Hospital, Odense, Denmark Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, 6700 Esbjerg, Denmark Department of Regional Health Research, University of Southern Denmark Odense University Hospital OPEN - Odense Patient data Explorative Network, The University of Southern Denmark, Odense, Denmark Research Unit of Health Sciences, Hospital of South West Jutland